Xponance Inc. Sells 63 Shares of Repligen Co. (NASDAQ:RGEN)

Xponance Inc. decreased its position in Repligen Co. (NASDAQ:RGEN) by 0.7% during the 4th quarter, Holdings Channel.com reports. The fund owned 8,899 shares of the biotechnology company’s stock after selling 63 shares during the quarter. Xponance Inc.’s holdings in Repligen were worth $1,600,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the company. Signaturefd LLC lifted its stake in Repligen by 44.1% in the third quarter. Signaturefd LLC now owns 281 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 86 shares during the period. First Horizon Advisors Inc. raised its position in shares of Repligen by 14.8% during the third quarter. First Horizon Advisors Inc. now owns 675 shares of the biotechnology company’s stock worth $107,000 after purchasing an additional 87 shares during the period. Daiwa Securities Group Inc. raised its position in shares of Repligen by 3.2% during the third quarter. Daiwa Securities Group Inc. now owns 3,200 shares of the biotechnology company’s stock worth $509,000 after purchasing an additional 100 shares during the period. State of Michigan Retirement System raised its position in shares of Repligen by 0.8% during the fourth quarter. State of Michigan Retirement System now owns 12,453 shares of the biotechnology company’s stock worth $2,239,000 after purchasing an additional 100 shares during the period. Finally, Teacher Retirement System of Texas grew its holdings in shares of Repligen by 2.5% during the third quarter. Teacher Retirement System of Texas now owns 4,098 shares of the biotechnology company’s stock worth $652,000 after buying an additional 101 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

RGEN has been the subject of a number of research reports. KeyCorp increased their price objective on Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a report on Thursday, February 15th. Stifel Nicolaus raised their price target on Repligen from $165.00 to $207.00 and gave the company a “buy” rating in a research note on Thursday, February 22nd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, Repligen currently has a consensus rating of “Moderate Buy” and a consensus target price of $196.70.

Repligen Stock Performance

Shares of NASDAQ RGEN opened at $171.28 on Wednesday. The company has a market capitalization of $9.56 billion, a P/E ratio of 237.89, a P/E/G ratio of 5.16 and a beta of 1.02. The stock has a 50 day moving average of $186.62 and a 200-day moving average of $173.56. The company has a current ratio of 7.02, a quick ratio of 5.75 and a debt-to-equity ratio of 0.26. Repligen Co. has a 12 month low of $110.45 and a 12 month high of $211.13.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $0.33 earnings per share for the quarter, hitting the consensus estimate of $0.33. The business had revenue of $155.74 million during the quarter, compared to analysts’ expectations of $155.38 million. Repligen had a return on equity of 5.00% and a net margin of 6.51%. The firm’s revenue for the quarter was down 16.6% compared to the same quarter last year. During the same period last year, the firm posted $0.68 EPS. As a group, equities research analysts predict that Repligen Co. will post 1.46 EPS for the current year.

Insider Buying and Selling

In related news, VP Ralf Kuriyel sold 3,517 shares of Repligen stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $193.73, for a total transaction of $681,348.41. Following the completion of the sale, the vice president now directly owns 24,260 shares of the company’s stock, valued at approximately $4,699,889.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Repligen news, CEO Anthony Hunt sold 16,707 shares of Repligen stock in a transaction on Friday, March 8th. The stock was sold at an average price of $197.44, for a total value of $3,298,630.08. Following the completion of the transaction, the chief executive officer now directly owns 185,249 shares of the company’s stock, valued at approximately $36,575,562.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Ralf Kuriyel sold 3,517 shares of Repligen stock in a transaction on Monday, March 11th. The shares were sold at an average price of $193.73, for a total value of $681,348.41. Following the completion of the transaction, the vice president now directly owns 24,260 shares of the company’s stock, valued at $4,699,889.80. The disclosure for this sale can be found here. In the last ninety days, insiders sold 25,597 shares of company stock valued at $5,039,532. Insiders own 1.20% of the company’s stock.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.